April 10 (Reuters) - Avivagen Inc VIV.V -
* Avivagen reports positive proof of concept in preventing C. Difficile infection
* Study demonstrated highest dose of OxC-beta technology tested increased survivability in mice versus un-supplemented mouse control group Source text for Eikon: ID:nGNXNSKNDa Further company coverage: VIV.V